Background
Methods
Data source
Study population
Lifetime risk
Attributable risk among the exposed and population attributable risk
Outcomes
Analysis
Lifetime risk
Attributable risk among the exposed and population attributable risk
Results
Baseline characteristics at incident T2D diagnosis
All T2D | CVRD free | HF only | CKD only | MI only | Stroke only | PAD only | Multiple CVRD | ||
---|---|---|---|---|---|---|---|---|---|
473,399 | 276,941 | 5310 | 35,019 | 2721 | 17,044 | 5898 | 126,615 | ||
Follow-up (years) | Median [IQR] | 6 [3 , 9] | 6 [3 , 10] | 4 [2 , 8] | 5 [3 , 9] | 6 [3 , 10] | 5 [3 , 9] | 6 [3 , 10] | 5 [3 , 9] |
Age (years) | Mean (SD) | 63.5 (14.4) | 58.3 (13.7) | 70.2 (13.4) | 71.8 (12.2) | 67.3 (12.4) | 69.3 (12.6) | 68.4 (11.1) | 70.9 (11.71) |
Female | N (%) | 216,273 (45.7%) | 128,516 (46.4%) | 2542 (47.9%) | 20,411 (58.3%) | 813 (29.9%) | 7760 (45.5%) | 2147 (36.4%) | 51,891 (41.0%) |
BMI | Mean (SD) | 31.5 (6.9) | 32.1 (7.0) | 32.7 (8.1) | 30.8 (6.7) | 30.6 (6.2) | 30.2 (6.4) | 29.9 (6.3) | 30.7 (6.40) |
Smoking status | Never | 69,360 (19.7%) | 40,209 (20.5%) | 765 (19.1%) | 6178 (23.4%) | 326 (16.3%) | 2333 (18.3%) | 633 (12.4%) | 18,348 (17.9%) |
Former | 162,659 (46.3%) | 82,255 (42.0%) | 2083 (51.9%) | 12,539 (47.5%) | 1054 (52.8%) | 6056 (47.6%) | 2364 (46.3%) | 54,739 (53.3%) | |
Current | 119,532 (34.0%) | 73,296 (37.4%) | 1162 (29.0%) | 7658 (29.0%) | 618 (30.9%) | 4325 (34.0%) | 2109 (41.3%) | 29,675 (28.9%) | |
HbA1c Category | < 7% | 131,242 (50.8%) | 66,677 (48.4%) | 1471 (51.9%) | 12,527 (55.8%) | 731 (50.0%) | 4931 (54.4%) | 1757 (46.8%) | 41,950 (53.1%) |
7-10% | 105,662 (40.9%) | 56,517 (41.1%) | 1148 (40.5%) | 8750 (39.0%) | 627 (42.9%) | 3557 (39.3%) | 1683 (44.8%) | 32,490 (41.1%) | |
> 10% | 21,574 (8.3%) | 14,451 (10.5%) | 213 (7.5%) | 1161 (5.2%) | 103 (7.0%) | 570 (6.3%) | 313 (8.3%) | 4604 (5.8%) | |
SBP (mmHg) | < 130 | 142,824 (32.2%) | 79,050 (30.8%) | 1944 (39.1%) | 9947 (29.7%) | 756 (31.7%) | 4890 (31.0%) | 1487 (26.7%) | 43,201 (35.8%) |
130–150 | 224,531 (50.7%) | 131,672 (51.3%) | 2256 (45.3%) | 17,648 (52.7%) | 1241 (52.0%) | 8191 (51.9%) | 2919 (52.4%) | 59,054 (48.9%) | |
150+ | 75,840 (17.1%) | 45,956 (17.9%) | 775 (15.6%) | 5894 (17.6%) | 391 (16.4%) | 2707 (17.1%) | 1165 (20.9%) | 18,437 (15.3%) | |
DBP (mmHg) | < 80 | 221,401 (50.0%) | 106,627 (41.5%) | 2858 (57.4%) | 19,960 (59.6%) | 1335 (55.9%) | 8489 (53.8%) | 3259 (58.5%) | 76,401 (63.3%) |
80–100 | 206,329 (46.6%) | 138,113 (53.8%) | 1962 (39.4%) | 12,820 (38.3%) | 1012 (42.4%) | 6899 (43.7%) | 2205 (39.6%) | 42,248 (35.0%) | |
100+ | 15,412 (3.5%) | 11,906 (4.6%) | 156 (3.1%) | 710 (2.1%) | 42 (1.8%) | 400 (2.5%) | 107 (1.9%) | 2019 (1.7%) | |
Atrial fibrillation | N (%) | 32,972 (7.0%) | 6392 (2.3%) | 1884 (35.5%) | 2321 (6.6%) | 206 (7.6%) | 1739 (10.2%) | 354 (6.0%) | 18,569 (14.7%) |
HDL (mmol/L) | Mean (SD) | 1.2 (0.37) | 1.2 (0.36) | 1.3 (0.38) | 1.3 (0.39) | 1.2 (0.35) | 1.3 (0.38) | 1.2 (0.37) | 1.2 (0.37) |
LDL (mmol/L) | Mean (SD) | 2.7 (1.03) | 2.9 (1.02) | 2.6 (0.94) | 2.6 (0.99) | 2.4 (0.96) | 2.4 (0.95) | 2.5 (1.02) | 2.3 (0.94) |
Triglyceride (mmol/L) | Median (IQR) | 1.7 [1.2 , 2.4] | 1.8 [1.2 , 2.5] | 1.6 [1.1 , 2.3] | 1.7 [1.2 , 2.3] | 1.6 [1.1 , 2.4] | 1.6 [1.1 , 2.3] | 1.7 [1.2 , 2.5] | 2.0 (1.29) |
Physical activity | Inactive | 83,736 (43.0%) | 39,805 (36.8%) | 1083 (52.1%) | 6565 (47.4%) | 388 (37.7%) | 3424 (50.6%) | 1166 (49.8%) | 30,344 (51.5%) |
Moderately inactive | 17,637 (9.1%) | 11,148 (10.3%) | 193 (9.3%) | 1272 (9.2%) | 84 (8.2%) | 530 (7.8%) | 149 (6.4%) | 4144 (7.0%) | |
Moderately active | 70,060 (36.0%) | 41,557 (38.4%) | 606 (29.1%) | 4502 (32.5%) | 451 (43.8%) | 2159 (31.9%) | 798 (34.1%) | 19,655 (33.4%) | |
Active | 23,315 (12.0%) | 15,750 (14.5%) | 198 (9.5%) | 1503 (10.9%) | 106 (10.3%) | 655 (9.7%) | 227 (9.7%) | 4787 (8.1%) | |
CVD risk treatment | |||||||||
Low dose aspirin | 29.0% | 14.2% | 25.1% | 27.5% | 50.2% | 45.1% | 49.8% | 58.4% | |
Statins | 53.1% | 40.4% | 48.7% | 58.9% | 64.2% | 68.5% | 69.5% | 76.5% | |
Anti-hypertensive medications: | 55.6% | 43.1% | 73.2% | 73.0% | 59.5% | 63.9% | 62.2% | 75.5% | |
ACE inhibitors | 34.7% | 26.0% | 51.7% | 44.2% | 40.9% | 39.5% | 38.7% | 48.9% | |
ARBs | 13.1% | 9.3% | 17.7% | 20.9% | 13.0% | 13.2% | 12.6% | 18.7% | |
Calcium channel blockers | 26.3% | 20.1% | 25.0% | 35.9% | 22.6% | 33.4% | 33.2% | 36.0% | |
Beta blockers | 23.0% | 11.1% | 41.0% | 23.3% | 40.1% | 19.8% | 13.7% | 48.2% | |
Potassium-sparing diuretics | 3.6% | 1.2% | 19.4% | 3.5% | 2.5% | 2.1% | 2.1% | 7.8% | |
Loop diuretics | 12.7% | 4.2% | 55.5% | 15.6% | 9.5% | 10.1% | 9.7% | 27.6% | |
Thiazides | 13.9% | 12.5% | 10.8% | 22.7% | 11.9% | 18.5% | 18.4% | 14.0% | |
Warfarin | 5.2% | 1.7% | 26.0% | 4.9% | 5.7% | 7.6% | 6.7% | 10.9% | |
P2Y12 inhibitors | 4.8% | 0.4% | 1.5% | 1.1% | 7.0% | 14.8% | 8.3% | 14.1% | |
Other antiplatelets | 26.2% | 12.7% | 22.4% | 24.7% | 45.2% | 42.5% | 44.4% | 53.1% | |
Corticosteroids | 19.9% | 16.8% | 25.6% | 22.2% | 15.6% | 20.4% | 20.6% | 25.4% | |
Any CVD risk treatment | 71.4% | 59.6% | 83.9% | 84.8% | 76.5% | 83.7% | 84.7% | 90.0% | |
Glucose-lowering treatment | |||||||||
SGLT-2 inhibitors | 0.2% | 0.2% | 0.2% | 0.2% | 0.5% | 0.1% | 0.3% | 0.2% | |
Metformin | 39.4% | 39.8% | 36.3% | 38.9% | 39.6% | 38.1% | 45.6% | 39.0% | |
Sulfonylurea | 15.5% | 12.6% | 15.7% | 22.0% | 16.1% | 16.1% | 22.1% | 19.5% | |
DPP-4 inhibitors | 1.9% | 1.6% | 1.6% | 2.9% | 1.8% | 1.5% | 1.8% | 2.2% | |
GLP-1RA | 0.5% | 0.5% | 0.7% | 0.5% | 0.6% | 0.3% | 0.7% | 0.5% | |
Metiglinides | 0.3% | 0.2% | 0.1% | 0.3% | 0.3% | 0.3% | 0.4% | 0.3% | |
Glitazones | 4.9% | 4.5% | 3.5% | 7.0% | 5.3% | 4.2% | 7.5% | 5.3% | |
Acarbose | 0.2% | 0.1% | 0.2% | 0.3% | 0.2% | 0.2% | 0.4% | 0.3% | |
Insulins | 7.2% | 4.8% | 5.9% | 10.5% | 7.3% | 6.0% | 12.1% | 11.3% |
Lifetime risk
Baseline status | Outcomes | ||||||
---|---|---|---|---|---|---|---|
HF | CKD | MI | Stroke | PAD | CVD death | MARCE | |
Reference: CVRD free | 29.2 (27.5–29.7) | 53.6 (52.6–54.1) | 18.9 (17.2–19.3) | 20.2 (18.5–20.6) | 9.2 (8.1–9.5) | 40.5 (40.0–41.1) | 80.0 (79.7–80.4) |
HF only | – | 66.0 (65.2–70.6) | 25.7 (21.6–29.4) | 18.7 (13.2–21.7) | 12.8 (8.8–15.5) | 66.0 (65.0–69.4) | 97.1 (97.1–100) |
CKD only | 34.7 (32.9–36.2) | – | 20.7 (18.7–22.0) | 20.3 (18.2–21.6) | 13.0 (11.2–14.3) | 45.7 (44.3–47.2) | 93.3 (93.3–96.3) |
MI only | 44.0 (37.2–49.8) | 53.2 (49.1–58.8) | – | 24.4 (15.9–28.1) | 14.3 (9.1–17.9) | 60.3 (56.1–64.4) | 97.6 (97.6–100) |
Stroke only | 28.8 (25.5–30.5) | 54.5 (52.9–56.7) | 23.8 (20.4–25.8) | – | 12.3 (10.2–13.6) | 56.2 (54.7–57.9) | 89.2 (89.1–92.1) |
PAD only | 35.2 (30.0–38.4) | 56.0 (53.8–61.4) | 29.2 (21.4–33.7) | 27.7 (21.0–31.8) | – | 52.5 (49.0–56.0) | 90.8 (90.8–98.9) |
Attributable risk among the exposed and population attributable risk
Risk factors | Category | OR (95%CI) | Estimated risk | ARE | % of events (Pe) | PAR |
---|---|---|---|---|---|---|
Non-modifiable | ||||||
Age | < 45 | 1 | 0.030 | 11.1 | ||
45–54 | 1.55 (1.49, 1.61) | 0.045 | 0.345 | 17.5 | 0.060 | |
55–64 | 2.47 (2.38, 2.55) | 0.070 | 0.577 | 23.4 | 0.135 | |
65–74 | 4.35 (4.20, 4.50) | 0.118 | 0.747 | 24.3 | 0.181 | |
75–84 | 7.75 (7.47, 8.03) | 0.192 | 0.845 | 17.8 | 0.150 | |
85+ | 9.79 (9.38, 10.21) | 0.231 | 0.871 | 5.9 | 0.052 | |
Sex | Female | 1 | 0.514 | 45.7 | ||
Male | 1.20 (1.18, 1.23) | 0.559 | 0.082 | 54.3 | 0.044 | |
Modifiable | ||||||
Comorbidities | CVRD free | 1 | 0.045 | 58.5 | ||
HF only | 4.60 (4.20, 5.04) | 0.177 | 0.748 | 1.1 | 0.008 | |
CKD only | 2.86 (2.76, 2.96) | 0.118 | 0.621 | 7.4 | 0.046 | |
MI only | 4.29 (3.79, 4.85) | 0.167 | 0.733 | 0.6 | 0.004 | |
Stroke only | 2.17 (2.06, 2.28) | 0.092 | 0.515 | 3.6 | 0.019 | |
PAD only | 3.81 (3.54, 4.10) | 0.151 | 0.704 | 1.2 | 0.009 | |
Multiple CVRD | 4.69 (4.58, 4.79) | 0.180 | 0.751 | 27.6 | 0.207 | |
BMI | Normal (20–24) | 1 | 0.124 | 12.7 | ||
Under weight (< 20) | 0.96 (0.88, 1.04) | 0.120 | -0.039 | 1.6 | -0.001 | |
Over weight (25–29) | 0.99 (0.96, 1.03) | 0.123 | -0.005 | 31.6 | -0.002 | |
Obese (30–39) | 1.12 (1.09, 1.16) | 0.137 | 0.096 | 43.3 | 0.042 | |
Severely obese (40+) | 1.49 (1.42, 1.56) | 0.174 | 0.287 | 10.8 | 0.031 | |
Smoking | Never | 1 | 0.129 | 19.7 | ||
Former | 1.03 (1.00, 1.06) | 0.132 | 0.026 | 46.3 | 0.012 | |
Current | 1.15 (1.12, 1.19) | 0.146 | 0.117 | 34.0 | 0.040 | |
HbA1c | < 7% | 1 | 0.109 | 50.8 | ||
7–10% | 1.45 (1.42, 1.48) | 0.150 | 0.276 | 40.9 | 0.113 | |
10% | 1.96 (1.88, 2.04) | 0.192 | 0.436 | 8.3 | 0.036 | |
Hypertension | SBP < 150 and DBP < 100 | 1 | 0.134 | 83.3 | ||
SBP > 150 or DBP > 100 | 1.24 (1.21, 1.27) | 0.161 | 0.167 | 16.7 | 0.028 | |
High cholesterol | HDL ≥1 and LDL ≤3 and triglyceride ≤2.3 | 1 | 0.127 | 38.4 | ||
HDL ≤1 or LDL ≥3 or triglyceride ≥2.3 | 1.10 (1.08, 1.13) | 0.139 | 0.083 | 61.6 | 0.051 | |
Physical activity | Inactive | 2.19 (2.07, 2.32) | 0.140 | 0.506 | 43.0 | 0.217 |
Moderately inactive | 1.01 (0.93, 1.09) | 0.069 | 0.005 | 9.1 | 0.000 | |
Moderately active | 1.49 (1.41, 1.58) | 0.100 | 0.307 | 36.0 | 0.110 | |
Active | 1 | 0.069 | 12.0 | |||
Overall cardiovascular health* | Ideal | 1 | 0.080 | 1.0 | ||
≥1 risk factor | 1.84 (1.72, 1.97) | 0.138 | 0.419 | 99.0 | 0.415 |